Gesynta Pharma key facts
as of Oct 2026- Developer of a clinical-stage pharmaceutical portfolio designed to treat inflammatory diseases by inhibiting pro-inflammatory pathways.
- Gesynta Pharma is valued at approximately $42.8M as of Oct 2026 (last reported valuation).
- It has raised $77.8M; the latest was Later Stage VC ($36.8M) in Oct 2025.
- Notable investors include Innovestor, Industrifonden, Nordic Mentor Network For Entrepreneurship, Amboy Street Ventures, Stephen Industries — 17 tracked in total.
- Status: Privately Held (backing).
Gesynta Pharma's last reported valuation, Dec 2021. Nothing priced has surfaced since.
- ·The complete investor list: 17 names
- ·Watch Gesynta Pharma: the Monday email on marks, rounds and moves
Gesynta Pharma funding rounds
No funding rounds for Gesynta Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Gesynta Pharma
17+Gesynta Pharma valuation
Gesynta Pharma's last reported valuation was $42.8 million in Dec 2021. No priced round, secondary trade or fund mark has surfaced since.
Gesynta Pharma investors
17 investors are on record for Gesynta Pharma, including Innovestor, Industrifonden, Nordic Mentor Network For Entrepreneurship and Amboy Street Ventures.
About Gesynta Pharma
Developer of a clinical-stage pharmaceutical portfolio designed to treat inflammatory diseases by inhibiting pro-inflammatory pathways. The company offers selective enzyme-targeting drug candidates with favorable safety and pharmacological profiles, enabling patients with inflammatory conditions such as endometriosis to experience non-hormonal symptom relief and improved quality of life.
- Sector
- Healthcare
- HQ
- Stockholm, Sweden
- Founded
- 2017
- Employees
- 11
- Website
- gesynta.se/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.